| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
8,614 |
6,317 |
$1.05M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,885 |
4,748 |
$120K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,687 |
4,183 |
$104K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,675 |
1,009 |
$21K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
409 |
332 |
$18K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,527 |
1,247 |
$17K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
685 |
543 |
$15K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
223 |
204 |
$11K |
| 99460 |
|
179 |
160 |
$10K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
29 |
27 |
$6K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
157 |
129 |
$5K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
514 |
395 |
$4K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
165 |
144 |
$2K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
39 |
37 |
$2K |
| 99462 |
|
66 |
56 |
$2K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
302 |
256 |
$2K |
| 36416 |
|
634 |
561 |
$1K |
| 90700 |
|
182 |
143 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
139 |
112 |
$936.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
24 |
16 |
$566.93 |
| 99001 |
|
165 |
144 |
$504.00 |
| 90647 |
|
80 |
63 |
$488.00 |
| 90670 |
|
75 |
54 |
$424.00 |
| 90713 |
|
65 |
55 |
$424.00 |
| 99173 |
|
180 |
164 |
$330.00 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
29 |
24 |
$318.48 |
| 83655 |
|
15 |
14 |
$210.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
144 |
113 |
$189.66 |
| 92552 |
|
15 |
14 |
$154.00 |
| 87807 |
|
13 |
13 |
$134.10 |
| 90686 |
|
19 |
13 |
$110.06 |
| 85018 |
|
177 |
161 |
$48.00 |
| 36415 |
Collection of venous blood by venipuncture |
33 |
24 |
$42.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
22 |
12 |
$30.86 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
111 |
102 |
$26.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
132 |
103 |
$21.98 |
| J7626 |
Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg |
96 |
80 |
$0.38 |
| 3078F |
|
1,352 |
1,177 |
$0.00 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
26 |
24 |
$0.00 |
| 87652 |
|
164 |
131 |
$0.00 |
| 3008F |
|
3,702 |
3,015 |
$0.00 |
| 3044F |
|
436 |
355 |
$0.00 |
| 3079F |
|
364 |
313 |
$0.00 |
| 3074F |
|
1,674 |
1,452 |
$0.00 |
| G2025 |
Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only |
258 |
140 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
88 |
70 |
$0.00 |
| Q3014 |
Telehealth originating site facility fee |
218 |
136 |
$0.00 |
| 94761 |
|
104 |
83 |
$0.00 |
| 87650 |
|
35 |
30 |
$0.00 |
| 96112 |
|
28 |
21 |
$0.00 |